M&A / Deals URA and Lilly join forces to harmonise drug-wearable obesity care Pharmaceutical TechnologyLilly and URA's partnership marks another high-profile collaboration between the consumer health and life science sectors.Metabolic & GLP-1Read full story pharminent June 24, 2026 (Last updated: June 26, 2026) Pharmaceutical Technology Lilly and URA’s partnership marks another high-profile collaboration between the consumer health and life science sectors. Metabolic & GLP-1 Read full story Post navigation Previous: Boehringer and Combotope partner for cancer antibodiesNext: Lundbeck to present new Vyepti and bocunebart data at EAN 2026 Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026